Brokerages Set C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target at $10.67

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) has received an average rating of "Moderate Buy" from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $10.67.

Several research analysts have recently weighed in on CCCC shares. Stephens began coverage on shares of C4 Therapeutics in a research note on Monday, November 18th. They issued an "equal weight" rating and a $4.00 target price for the company. Wells Fargo & Company raised shares of C4 Therapeutics from an "equal weight" rating to an "overweight" rating and upped their price objective for the company from $8.00 to $12.00 in a research report on Thursday.

C4 Therapeutics Price Performance

NASDAQ CCCC traded up $0.10 during trading hours on Friday, hitting $3.95. The company had a trading volume of 3,811,127 shares, compared to its average volume of 2,089,906. The firm's 50 day moving average is $5.04 and its 200 day moving average is $5.44. C4 Therapeutics has a fifty-two week low of $3.61 and a fifty-two week high of $11.88. The company has a market capitalization of $278.83 million, a price-to-earnings ratio of -2.32 and a beta of 2.92.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.05. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. The business had revenue of $15.36 million for the quarter, compared to the consensus estimate of $5.95 million. On average, equities analysts anticipate that C4 Therapeutics will post -1.52 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CCCC. Point72 DIFC Ltd acquired a new stake in shares of C4 Therapeutics in the third quarter valued at approximately $51,000. Headlands Technologies LLC bought a new stake in C4 Therapeutics during the 2nd quarter valued at $45,000. Cynosure Group LLC acquired a new position in C4 Therapeutics during the 3rd quarter worth $57,000. B. Riley Wealth Advisors Inc. bought a new position in shares of C4 Therapeutics in the second quarter worth $51,000. Finally, Aigen Investment Management LP acquired a new position in shares of C4 Therapeutics during the third quarter valued at $82,000. Institutional investors and hedge funds own 78.81% of the company's stock.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.